Skip to main content

ESTUDIO OPTIFLU-CAR-T - OPTIMIZACION DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSION DE LA TERAPIA DE CELULAS T CON RECEPTOR DE ANTIGENO QUIMÉRICO (CAR-T) EN PACIENTES CON INSUFICIENCIA RENAL

PI21/00197

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre HOSPITAL VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Towards Personalized Lymphodepletion, A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy

  • Varela-González-Aller, Javier
  • Sánchez-Salinas, Mario Andrés
  • Troconiz, Iñaki|||0000-0003-3700-8658
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Alonso-Martínez, Carla|||0000-0003-0032-4059
  • Carreras Soler, Maria Josep|||0000-0001-6482-9940
  • Carpio Segura, Cecilia del Carmen|||0000-0001-9346-0134
  • Farriols Danés, Anna
  • Guerra-González, María
  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • Rivera Sanchez, Lucas|||0000-0002-1875-9512
  • Feijoo, Samantha
  • Barba, Pere|||0000-0001-7076-7969
  • Miarons, Marta|||0000-0001-7847-1580
Background/Objectives: Optimal fludarabine dosing in the conditioning regimen based on population pharmacokinetic analysis (popPK) can predict outcomes in patients receiving hematopoietic stem cell transplantation. To date, there is no popPK tailored for patients receiving fludarabine as part of the lymphodepleting regimen before chimeric antigen receptor (CAR) T-cell infusion. The objective of this study was to develop a PopPK model of fludarabine in patients receiving CAR T-cell therapy. Methods: A prospective study was conducted at a tertiary hospital, from January 2021 to July 2022. Demographic, clinical, and analytical variables were collected. Blood samples were obtained on days 1 and 3 of the lymphodepleting regimen at 1.5, 2, 7 and 24 h post-fludarabine doses, and 30 min prior to CART-cell infusion. Fludarabine levels were analyzed through an ultra-performance liquid chromatography tandem mass spectrometry assay based on liquid-liquid extraction. Population pharmacokinetic analysis modeling was performed using nonlinear mixed-effects models (NONMEM). Results: Fifty-six patients (59% male) with a median age of 59 years (range 23-82) received CAR T-cell therapy (38 [68%] axicabtagene ciloleucel, 18 [32%] tisagenlecleucel) for relapsed/refractory large B-cell lymphoma. A total of 348 samples were collected for model development. A three-compartment model with first-order elimination best described the data. Body size, as represented by weight (WGT) with allometric scaling, was a significant predictor of all pharmacokinetic parameters (p < 0.05). Estimated glomerular filtration rate (eGFR) and the CAR T-cell construct type also showed statistical significance for fludarabine clearance (CL) (p < 0.05). Clearance was differentiated into non-renal and renal components. Estimates of V1, V2 and V3 volumes (the apparent volume of distribution of the central, shallow and deep compartments) were 41.2, 14.5 and 10.8 L, respectively. Conclusions: WGT, eGFR and type of CAR-T were predictors of fludarabine pharmacokinetics. This model offers a step toward precision-guided lymphodepletion and might support individualized dosing to optimize efficacy and minimize toxicity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large Bcell lymphoma

  • Sánchez-Salinas, Mario Andrés
  • Varela-González-Aller, Javier
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Navarro Garcés, Víctor|||0000-0001-6925-4605
  • Troconiz, Iñaki|||0000-0003-3700-8658
  • Carpio Segura, Cecilia del Carmen|||0000-0001-9346-0134
  • Alonso-Martínez, Carla|||0000-0003-0032-4059
  • Carreras Soler, Maria Josep|||0000-0001-6482-9940
  • Farriols Danés, Anna
  • Guerra-González, María
  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • Rivera Sanchez, Lucas|||0000-0002-1875-9512
  • Feijoo, Samantha
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Valdivia, Carolina
  • Miarons, Marta|||0000-0001-7847-1580
  • Barba, Pere|||0000-0001-7076-7969
The impact of fludarabine pharmacokinetics (PK) on chimeric antigen receptor (CAR) T-cell outcomes is not fully elucidated. We hypothesized that, in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients, measured fludarabine exposure during lymphodepletion would correlate with CAR Tcell results. We conducted a prospective, single-center study including R/R LBCL patients treated with commercial, CD19-targeted CAR T-cell products. Up to seven plasma samples per patient were collected at predefined intervals during lymphodepletion. Fludarabine exposure (area under the curve, AUC) was estimated using a population PK model. An iterative cubic spline approach identified optimal AUC exposure ranges specific to each CAR-T product. The primary endpoint was progression-free survival (PFS). Among 54 patients with a median follow-up of 24.5 months, the median fludarabine AUC was 18.12 mg*h/L (IQR 14.56-20.55). Optimal exposure windows were 17.5-21.5 mg*h/L for axicabtagene ciloleucel (axi-cel) and 14.0-18.0 mg*h/L for tisagenlecleucel (tisa-cel), with 24 patients (44%) inside these ranges. Median PFS after CAR-T infusion was not reached vs 13.3 months in the optimal vs other cohort (p=0.03). In the multivariable analysis, optimal exposure remained independently associated with improved PFS (p=0.03), together with axi-cel treatment (p=0.03). CAR T-cell expansion and rates of any grade CRS, ICANS and hematotoxicity were similar between groups. In conclusion, prospective measurement of fludarabine exposure identified an optimal AUC window associated with prolonged PFS in R/R LBCL patients receiving CAR T-cell therapy. These findings support the integration of PK-guided fludarabine dosing to enhance therapeutic outcomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

  • Kwon, Mi|||0000-0002-3855-7774
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Reguera-Ortega, Juan Luis
  • López Corral, Lucia|||0000-0003-1908-5596
  • Morales, Rafael Hernani
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Guerreiro, Manuel
  • Caballero, Ana Carolina|||0000-0002-4950-5259
  • Domínguez, María Luisa Guerra
  • Sánchez Pina, José María|||0000-0002-9181-0900
  • Mussetti, Alberto|||0000-0002-4088-036X
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Bastos, Mariana|||0000-0002-9431-4646
  • Catalá, Eva|||0000-0003-3478-9110
  • Delgado, Javier
  • Henriquez, Hugo Luzardo
  • Sanz, Jaime|||0000-0001-6934-4619
  • Calbacho, Maria|||0000-0001-8106-4863
  • Bailén, Rebeca|||0000-0003-2838-1776
  • Carpio Segura, Cecilia del Carmen|||0000-0001-9346-0134
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Sureda, Anna|||0000-0002-1238-6970
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113
  • Martínez Cibrián, Núria|||0000-0002-8688-1202
  • Martin, Jose Luis Diez
  • Martín, Alejandro
  • Barba, Pere|||0000-0001-7076-7969
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P =0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P =0.003, and 42% vs. 16%, P <0.001, respectively). Infections in the first 6 months post-infusion were also more common in patients treated with axi-cel (38% vs. 25%, P =0.033). Non-relapse mortality was not significantly different between the axi-cel and tisa-cel groups (7% and 4%, respectively, P =0.298). With a median follow-up of 9.2 months, median PFS and OS were 5.9 and 3 months, and 13.9 and 11.2 months for axi-cel and tisa-cel, respectively. The 12-month PFS and OS for axi-cel and tisa-cel were 41% and 33% (P =0.195), 51% and 47% (P =0.191), respectively. Factors associated with lower OS in the multivariate analysis were increased lactate dehydrogenase, ECOG ≥2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those receiving tisa-cel. Efficacy was not significantly different between both products.